ANIK - NASDAQ
Anika Therapeutics, Inc.
$14.41
+0.49%Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
At a Glance
Live Snapshotanik
Selling, General and Administrative Expenses
Last Annual Value
49.09M
3-Year CAGR
-1%
5-Year CAGR
-4%
10-Year CAGR
13%
Anika Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Anika Therapeutics, Inc. NASDAQ:ANIK | 49.09M | -6.4% | -7.9% | 10.5% | |
 Owlet, Inc. NYSE:OWLT | 47.70M | 5.3% | -7.2% | N/A | |
 LENSAR, Inc. NASDAQ:LNSR | 45.16M | 20.0% | 13.6% | N/A | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 15.96M | 4.3% | 7.1% | 9.4% | |
 DocGo Inc. NASDAQ:DCGO | 158.69M | 1.2% | 13.7% | N/A | |
 Microbot Medical Inc. NASDAQ:MBOT | 8.46M | 27.0% | 9.4% | -0.4% | |
 AVITA Medical, Inc. NASDAQ:RCEL | 79.91M | 6.8% | 16.5% | 19.1% | |
 MaxCyte, Inc. NASDAQ:MXCT | 47.04M | -6.2% | 8.2% | 18.0% | |
 Apyx Medical Corporation NASDAQ:APYX | 36.12M | -9.6% | -3.8% | 6.6% | |
 Lucid Diagnostics Inc. NASDAQ:LUCD | 41.58B | 952.5% | 370.5% | N/A | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 6.63M | 1.8% | -1.3% | 9.4% |
Anika Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ANIK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.